Federal Project Grant Award Summary

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $421,400 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) to 3D Bioanalytix, Inc. on July 1, 2026, with a completion date of April 30, 2028. The funding supports the development and validation of the Covalent Protein Painting (CPP) platform, with specific focus on the AmyFold assay—a first-in-class blood-based structural biomarker test designed to detect misfolded transthyretin (TTR) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This mass spectrometry-based diagnostic tool addresses a critical gap in current clinical practice by enabling early detection of protein misfolding-driven cardiovascular disease at pre-symptomatic stages, where existing imaging, echocardiography, and conventional biomarker approaches fail to identify disease.

Under this award, 3D Bioanalytix will optimize and validate the analytical performance and reproducibility of the AmyFold assay, demonstrate its capability for pre-symptomatic detection in at-risk patient populations, and establish the broader applicability of the CPP platform to other heart, lung, and blood conditions including unexplained heart failure. The assay has demonstrated greater than 95% sensitivity and specificity in blinded pilot studies, positioning it as a transformative tool for earlier diagnosis, improved disease monitoring, and enhanced patient access to disease-modifying therapies that may prevent or reverse disease progression.